A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer
Abstract The integration of targeted therapy and immunotherapy into adjuvant treatments for early-stage non-small cell lung cancer (NSCLC) remains challenging. This study aimed to compare the efficacy and safety of all available adjuvant treatment options. Randomized controlled trials (RCTs) publish...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-05823-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768805253775360 |
|---|---|
| author | Sunatee Sa-nguansai Sasivimol Rattanasiri Prapaporn Pornsuriyasak Pawin Numthavaj Gareth J. McKay John Attia Ammarin Thakkinstian |
| author_facet | Sunatee Sa-nguansai Sasivimol Rattanasiri Prapaporn Pornsuriyasak Pawin Numthavaj Gareth J. McKay John Attia Ammarin Thakkinstian |
| author_sort | Sunatee Sa-nguansai |
| collection | DOAJ |
| description | Abstract The integration of targeted therapy and immunotherapy into adjuvant treatments for early-stage non-small cell lung cancer (NSCLC) remains challenging. This study aimed to compare the efficacy and safety of all available adjuvant treatment options. Randomized controlled trials (RCTs) published up to August 15, 2023, were identified from MEDLINE, Scopus, and Cochrane CENTRAL. RCTs were included if they studied early-stage NSCLC and compared any adjuvant systemic targeted therapy or immunotherapy with adjuvant chemotherapy/placebo. This study was registered with PROSPERO, CRD42022351290. Individual patient data were generated based on data extracted from Kaplan–Meier curves. A parametric survival model was used to estimate the median time for disease-free survival (DFS) and overall survival (OS). A two-stage network meta-analysis (NMA) was applied to estimate the hazard ratio (HR) for DFS and OS, in addition to the risk ratio (RR) of severe adverse events (SAE). Nineteen RCTs (n = 9,438) were included for assessing the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), vascular endothelial growth factor (VEGF) inhibitors, immune checkpoint inhibitor (ICI) immunotherapy, and non-ICI immunotherapy. DFS in EGFR-TKIs and ICI immunotherapy was longer than chemotherapy/placebo, with a median time of 69.24, 53.47, and 39.49 months, respectively. EGFR-TKIs had a 46% significantly lower risk of recurrence [HR = 0.54 (95% CI: 0.38, 0.77)] than chemotherapy/placebo. Both EGFR-TKIs and ICI immunotherapy appeared to improve OS compared to chemotherapy or placebo, but both treatments also had an increased risk of SAE; however, neither result was statistically significant. This study indicates that EGFR-TKIs might be the best treatment regimen for reducing recurrence with an intermediate risk of SAE. |
| format | Article |
| id | doaj-art-5ea3e9310d7f405a8d35e5e7d56a2ac0 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-5ea3e9310d7f405a8d35e5e7d56a2ac02025-08-20T03:03:40ZengNature PortfolioScientific Reports2045-23222025-07-0115111210.1038/s41598-025-05823-2A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancerSunatee Sa-nguansai0Sasivimol Rattanasiri1Prapaporn Pornsuriyasak2Pawin Numthavaj3Gareth J. McKay4John Attia5Ammarin Thakkinstian6Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityDepartment of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityDepartment of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityDepartment of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityCentre for Public Health, Queen’s University BelfastSchool of Medicine and Public Health, University of NewcastleDepartment of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityAbstract The integration of targeted therapy and immunotherapy into adjuvant treatments for early-stage non-small cell lung cancer (NSCLC) remains challenging. This study aimed to compare the efficacy and safety of all available adjuvant treatment options. Randomized controlled trials (RCTs) published up to August 15, 2023, were identified from MEDLINE, Scopus, and Cochrane CENTRAL. RCTs were included if they studied early-stage NSCLC and compared any adjuvant systemic targeted therapy or immunotherapy with adjuvant chemotherapy/placebo. This study was registered with PROSPERO, CRD42022351290. Individual patient data were generated based on data extracted from Kaplan–Meier curves. A parametric survival model was used to estimate the median time for disease-free survival (DFS) and overall survival (OS). A two-stage network meta-analysis (NMA) was applied to estimate the hazard ratio (HR) for DFS and OS, in addition to the risk ratio (RR) of severe adverse events (SAE). Nineteen RCTs (n = 9,438) were included for assessing the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), vascular endothelial growth factor (VEGF) inhibitors, immune checkpoint inhibitor (ICI) immunotherapy, and non-ICI immunotherapy. DFS in EGFR-TKIs and ICI immunotherapy was longer than chemotherapy/placebo, with a median time of 69.24, 53.47, and 39.49 months, respectively. EGFR-TKIs had a 46% significantly lower risk of recurrence [HR = 0.54 (95% CI: 0.38, 0.77)] than chemotherapy/placebo. Both EGFR-TKIs and ICI immunotherapy appeared to improve OS compared to chemotherapy or placebo, but both treatments also had an increased risk of SAE; however, neither result was statistically significant. This study indicates that EGFR-TKIs might be the best treatment regimen for reducing recurrence with an intermediate risk of SAE.https://doi.org/10.1038/s41598-025-05823-2Non-small cell lung cancerAdjuvant therapyTargeted therapyImmunotherapyNetwork meta-analysisDisease-free survival |
| spellingShingle | Sunatee Sa-nguansai Sasivimol Rattanasiri Prapaporn Pornsuriyasak Pawin Numthavaj Gareth J. McKay John Attia Ammarin Thakkinstian A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer Scientific Reports Non-small cell lung cancer Adjuvant therapy Targeted therapy Immunotherapy Network meta-analysis Disease-free survival |
| title | A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer |
| title_full | A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer |
| title_fullStr | A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer |
| title_full_unstemmed | A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer |
| title_short | A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer |
| title_sort | network meta analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non small cell lung cancer |
| topic | Non-small cell lung cancer Adjuvant therapy Targeted therapy Immunotherapy Network meta-analysis Disease-free survival |
| url | https://doi.org/10.1038/s41598-025-05823-2 |
| work_keys_str_mv | AT sunateesanguansai anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT sasivimolrattanasiri anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT prapapornpornsuriyasak anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT pawinnumthavaj anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT garethjmckay anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT johnattia anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT ammarinthakkinstian anetworkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT sunateesanguansai networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT sasivimolrattanasiri networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT prapapornpornsuriyasak networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT pawinnumthavaj networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT garethjmckay networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT johnattia networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer AT ammarinthakkinstian networkmetaanalysisofefficacyandsafetyofadjuvanttargetedtherapyorimmunotherapyinnonsmallcelllungcancer |